[ad_1]
Demonstrations and case studies demonstrate the success of causal machine learning-based techniques in planning and executing adaptive trials in lupus, diabetes, and other clinical indications
boston, April 8, 2024 /PRNewswire/—— fifth stagea pioneer in causal machine learning (ML) for clinical trial analysis and optimization, today announced that company executives will be present at five upcoming leading industry events in May and June.
“Machine learning is becoming an important tool for data-driven decision-making in drug development,” said Dr. Raviv Pryluk, CEO and co-founder of PhaseV. “We are proud to be invited to speak and host a session on the use of advanced machine learning in clinical trials. and has seen interest in this area grow rapidly. Our presentation will demonstrate the real-world impact of our technology to ensure significantly more precise and efficient clinical trials.”
PhaseV executives, partners and industry leaders will attend the following events:
- Clinical Trials Association 45th Annual Meeting
date: May 19-22, 2024
City: Boston, Massachusetts
Promotional meeting: Case study: Increase efficiency and facilitate informed decision-making by clinical trial teams using interactive adaptive trial AI simulation tools - FY2024 Generic Drug Science Research Program Public Workshop
date: May 20-21, 2024
City: FDA White Oak Campus, MD
Promotional meeting: Integrate AI/ML tools with regulatory information and data - EULAR 2024 Conference
date: June 12-15, 2024
City: vienna, austria
Promotional meeting: Case study on optimizing lupus adaptive trials using proprietary ML-based technology - DIA 2024 Global Annual Conference
date: June 16-20, 2024
City: San Diego, California
host a meeting:
– Machine learning and simulation facilitate clinical trials
– Recruitment optimization in clinical trials: looking toward an adaptive future - American Diabetes Association 84th Scientific Sessions
date: June 21-24, 2024
City: Orlando, Florida
Promotional meeting: Oramed Pharmaceuticals and PhaseV Abstract on Machine Learning-Based Optimization of Patient Eligibility for Oral Insulin Therapy: Post-hoc Analysis of Phase III Trial Results
PhaseV’s platform leverages proprietary causal inference and machine learning tools to perform retrospective analysis of Phase 2 and Phase 3 trials to “rescue” failed assets and/or optimize analysis to better prepare for the next trial. Be prepared. The platform also allows users to quickly evaluate millions of options (given specific considerations and constraints) and select the best option, enabling the prospective design and execution of dynamic adaptive clinical trials. This machine learning-driven adaptive process can significantly accelerate the clinical drug development process and increase certainty throughout the process, enabling more efficient, targeted, and ultimately more successful clinical trials.
PhaseV’s solutions are used by global pharmaceutical companies, biotech innovators and CROs across a broad range of therapeutic indications, including oncology, endocrinology, autoimmune diseases, rare diseases and more.
About the fifth issue
PhaseV harnesses the power of advanced causal inference and pushes the boundaries of machine learning to detect hidden signals in clinical data and extract actionable insights to plan optimal next steps. The company’s technology enables the optimal design and closed-loop execution of adaptive clinical trials, improving efficiency and success. PhaseV is driving a paradigm shift in clinical trials to bring new treatments to more patients with more precision and effectiveness.For more information, please visit www.phaseVtrials.com and follow us LinkedIn.
Media contact information:
FINN Phase 5 Partner
Aviva Sapir
[email protected]
929-588-2014
Logo – https://mma.prnewswire.com/media/2267452/PhaseV_logo.jpg
Source: Stage Five
[ad_2]
Source link